The GLP-1 monthly cost guide puts cash prices in context. Coverage can change what a patient pays without changing the published price, so this analysis looks at insurance and access after the label changed.
What changed, and when
Two things happened in March 2024. The FDA added an indication to Wegovy: reducing cardiovascular events in adults with overweight or obesity and established cardiovascular disease. And Medicare Part D began covering it for that indication. [1]
The 2024 coverage change applied to the new cardiovascular indication. Since July 2026, the separate Medicare GLP-1 Bridge has offered certain GLP-1s to eligible beneficiaries for weight management outside the regular Part D benefit.
What happened to volume
National prescription data from September 2023 to September 2024 show total semaglutide use rising, with Wegovy up by 136.4% relative to the period before the change — the largest relative increase of any semaglutide product.
Through Medicare Part D, Wegovy rose by 598.1%. The authors’ regression associated the policy changes with an estimated 592,624 additional fills by September 2024.
Who qualified under the 2024 change
The cardiovascular indication applies to adults with established cardiovascular disease and overweight or obesity. The study’s observation period ended in September 2024, before the GLP-1 Bridge began. If you have insurance through work, the employer coverage guide explains how to check your plan’s criteria for the condition being treated.
What fill counts can tell you
A fill counts a prescription dispensed. A person can fill several prescriptions, so the study does not measure the number of people who started treatment. The guide to absolute treatment effects explains how trials measure events prevented. This study measured pharmacy use by payer and did not report what individual patients paid.